Neurol. praxi. 2014;15(6):319-323

The individual preferences in choice of suitable MS treatment therapy

MUDr. Marta Vachová
Neurologické oddělení, KZ a.s. – Nemocnice Teplice, o.z.

The decision of the type of treatment according actual health condition and personal issue of the patient is crutial for multiple sclerosis therapy. Right choice is important for adherence and effectiveness of that. We talk about personalized medicine. The basic therapeutic recommendations are based on the dates from classical clinical studies and statistically defined effectivity of the therapy. The individual strategy is necessity for maximum of the effectiveness.

Keywords: multiple sclerosis, personalized medicine, effectiveness of the therapy, adherence, adverse events in multiple sclerosis therapy

Published: December 20, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vachová M. The individual preferences in choice of suitable MS treatment therapy. Neurol. praxi. 2014;15(6):319-323.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cadavit D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD. Efficacy of treatment of MS with IFN beta1b or glatiramer acetatte by monthly brain MRI in the BECAME study. Neurology 2009; 72(23): 1976-1983. Go to original source... Go to PubMed...
    2. Cohen JA, Barhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. TRANSFORMS Study Group. Oral fingolimod or intramuskular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-415. Go to original source... Go to PubMed...
    3. Comi G, Filippi M, Barhof F, Durelli L, Edan G, Fernández O, Hartung H, Seeldrayers P, S?rensen PS, Rovaris M, Martinelli V, Hommes OR. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576-1582. Go to original source... Go to PubMed...
    4. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M. PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrom (PreCISe study). A randomised, double blind, placebo-controlled trial. Lancet 2009; 374(9700): 1503-1511. Go to original source... Go to PubMed...
    5. Havrdova E, Galeta S, Hutchinson M, Stefoski D, Bates D, Polman ChH, O´Conor PW, Giovannoni G, Philips T, Lublin F, Pace A, Kim R, Hyde R. Effet of natlizumab on clinical and radiological disease aktivity in multiple sclerosis: retrospective analysis of the Natalizumab safety and Efficacy in Relapsing-Remiting Multiple sclerosis (AFFIRM) study. Lancet Neurol 2009; (3): 254-260. Go to original source... Go to PubMed...
    6. Havrdová, a kol. Roztroušená Skleróza. Mladá Fronta, Praha 2013.
    7. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH. A phase III trial of intramuscular recombinant interferon beta as treatment for exarerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG). Multiple scler. 1995 Jun 1 (2): 118-135. Go to original source... Go to PubMed...
    8. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheideidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. CHAMPS Study Group. Intramuscular interferon beta 1a therapy initiated during a first demyelinatitng event. In multiple sclerosis. N Eng J Med 2000; 343: 898-904. Go to original source... Go to PubMed...
    9. Johson KP, Brooks BR, Cohen JA, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Dolinsky JS. Copolymer 1 reduces relaps rate and improves disability in relapsing-remitting multiple scklerosis: results of phase III multicenter, doble-blind placebo.controlled trial. The copolymr 1 Multiple sclerosis Study Group. Neurology 1995; 45(7): 1268-1276. Go to original source... Go to PubMed...
    10. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C. BENEFIT Study Group. Benefit Study Group. Long-term effect of early treatment with the interferon beta 1-b after first clinical event suggestive of multiple sclerosis: 5-years active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987-997. Go to original source... Go to PubMed...
    11. Kappos L, Radue EW, O´Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 387-401. Go to original source... Go to PubMed...
    12. Mikol DD, Barhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B. REGARD study group. Regard Study group. Comparison of subcutaneous interferon beta 1-a with glatiramer acetate in patient with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Reapsing MS deisease (REGARD) study): multicentre, randomised, parallel, open label trial. Lanct Neurol 2008; 7(10): 903-914. Go to original source... Go to PubMed...
    13. Polman CH, O?Ćonor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. AFFIRM Investigators. AFFIRM Investigators. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis N engl J Med 2006; 354(9): 899-910. Go to original source... Go to PubMed...
    14. Study group. Randomised double-blind placebo-controlled study of interferon beta 1-a in relapsing/remitting multipe sclerosis. PRISMS Prevention of Relapses and Disability by Interferonbeta-1a Subcutaneously in Multiple Scerosis. Lancet 1998; 352(91 39): 1498-504. Go to original source...
    15. The IFNB Multiple sclerosis Study Group and the University of of British Columbia MS/MRI Analysis Group. Interferon beta-1b in treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995 Jul; 45(7): 1275-1285.
    16. Tremlett HL, Oger J. Neurology 2003; 61: 551-554.
    17. SmPC Avonex, Betaferon, Extavia, Rebif Copaxone, Gilenya, Tysabri. Dostupné www.sukl.cz/databáze léků.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.